These novel medications , Retatrutide, represent a significant advancement in addressing type 2 diabetes and possibly related conditions . They all are grouped as GLP-1 hormone agonists , meaning they to replicate the endogenous GLP-1 hormone , stimulating insulin production and reducing hunger .